Key Highlights
- $21 million Series A raised to scale organoid-AI platform and replace animal models in early drug discovery.
- 8 pharma partners onboard, including 3 Fortune 500 firms testing over 50 compounds on Parallel Bio’s human-immune system in a dish.
- First preclinical success with Centivax validates platform’s ability to predict human immune responses before clinical trials begin.
Organoid-AI Platform Aims to Transform Preclinical Drug Discovery
Parallel Bio’s proprietary platform replicates the human immune system using lymph-node organoids powered by automation and AI. By enabling “Clinical Trials in a Dish,” it offers drug developers a predictive, scalable, and human-relevant alternative to animal models. The platform allows pharma companies to evaluate immune responses, safety, and efficacy in a lab-grown human system—helping eliminate poor candidates before they reach patients.
$21M in New Capital Fuels Platform Expansion and Scientific Talent
Led by AIX Ventures, the Series A funding round includes notable names like Salesforce CEO Marc Benioff, Metaplanet, and Amplo. With nearly $30M raised to date, Parallel Bio will now scale its AI and robotics infrastructure, grow its cross-functional team, and meet rising pharma demand for accurate, human-first testing models. The capital also strengthens the company’s position as a next-gen partner to biopharma R&D teams globally.
Centivax Flu Vaccine Validated in First Human Organoid Trial
Parallel Bio’s first major preclinical milestone came in collaboration with Centivax, which used the platform to test its universal flu vaccine, Centi-Flu. The results confirmed robust immune activation, including B cell and CD4+/CD8+ T cell responses—even against non-included strains. This proof-of-concept demonstrates that Parallel Bio can de-risk drug candidates by generating real-time, patient-like data ahead of traditional clinical trials.
From Mice to Miniature Immune Systems: A New Industry Standard?
With a mission to replace animal models, Parallel Bio’s founders—scientists behind the world’s first scalable human immune organoid—believe the industry is ready for a paradigm shift. “We’re flipping the failure rate of drug development,” says CEO Robert DiFazio. Co-founder Juliana Hilliard adds: “Our goal is to cut $2 billion and 9 years from every new drug by starting with humans from day one.” With 95% of drugs still failing in human trials, the company’s “human-first” approach could define the next gold standard in precision drug discovery.
About Parallel Bio
Parallel Bio is pioneering a human-first approach to drug discovery by combining immune organoids and artificial intelligence to create highly accurate models of the human immune system. Founded in 2021 and based in Cambridge, Massachusetts, the company’s breakthrough platform replicates immune responses across diverse populations, enabling pharmaceutical partners to predict drug safety and efficacy at the earliest stages. With its “Clinical Trial in a Dish” technology, Parallel Bio aims to dramatically reduce the cost, time, and failure rate of drug development—replacing outdated animal models with scalable, human-relevant solutions.
By
